Project Description

Unifying AI and Biotech

Genesis Therapeutics has created an innovative molecular AI platform using deep neural networks, biophysical simulation, and massively scalable computing infrastructure to help develop best-in-class clinical drug candidates for FDA approval processes and ultimate commercialization. Drugs developed through their process should have faster discovery and higher probability of clinical trial success.  Genesis also announced a partnership with biotech giant Genentech in which it will receive an upfront payment and be eligible to receive pre-clinical, clinical and regulatory milestone payments, as well as future royalties on Genentech’s sales of approved drugs resulting from the collaboration.  Andreessen Horowitz (a16z), Felicis Ventures, Jazz Venture Partners, Harpoon Ventures, and Propagator Ventures are also investors in the company.